(+)-Tetrandrine multiple interactions ISO RGD:619563 6480464 [arsenite co-treated with tetrandrine] results in decreased expression of ERBB2 protein CTD PMID:31934280 (+)-Tetrandrine decreases expression ISO RGD:619563 6480464 tetrandrine results in decreased expression of ERBB2 protein CTD PMID:31934280 (-)-epigallocatechin 3-gallate decreases phosphorylation ISO RGD:619563 6480464 epigallocatechin gallate results in decreased phosphorylation of ERBB2 protein CTD PMID:18618485 1,1,1-Trichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)ethane increases activity ISO RGD:619563 6480464 o, p'-DDT results in increased activity of ERBB2 protein CTD PMID:11222871 , PMID:9443065 1,2-dimethylhydrazine increases expression ISO RGD:10533 6480464 1, 2-Dimethylhydrazine results in increased expression of ERBB2 mRNA CTD PMID:22206623 17beta-estradiol multiple interactions ISO RGD:619563 6480464 [Cycloheximide co-treated with Estradiol] results in decreased expression of ERBB2 mRNA more ... CTD PMID:15072547 more ... 17beta-estradiol increases expression ISO RGD:10533 6480464 Estradiol results in increased expression of ERBB2 mRNA CTD PMID:17640349 17beta-estradiol multiple interactions ISO RGD:10533 6480464 [ERBB2 protein co-treated with ERBB3 protein] results in increased susceptibility to Estradiol CTD PMID:19861407 17beta-estradiol increases expression ISO RGD:619563 6480464 Estradiol results in increased expression of ERBB2 mRNA CTD PMID:17555868 17beta-estradiol decreases expression ISO RGD:619563 6480464 Estradiol results in decreased expression of ERBB2 mRNA, Estradiol results in decreased expression of ERBB2 protein CTD PMID:15072547 more ... 2,3,7,8-tetrachlorodibenzodioxine increases expression ISO RGD:619563 6480464 Tetrachlorodibenzodioxin results in increased expression of ERBB2 mRNA CTD PMID:11162886 , PMID:17555868 2,3,7,8-tetrachlorodibenzodioxine decreases expression ISO RGD:619563 6480464 Tetrachlorodibenzodioxin results in decreased expression of ERBB2 mRNA CTD PMID:26238291 2,3,7,8-tetrachlorodibenzodioxine affects expression ISO RGD:619563 6480464 Tetrachlorodibenzodioxin affects the expression of ERBB2 mRNA CTD PMID:22298810 , PMID:22574217 2,3,7,8-tetrachlorodibenzodioxine increases expression EXP 6480464 Tetrachlorodibenzodioxin results in increased expression of ERBB2 mRNA CTD PMID:21215274 , PMID:33387578 2,3,7,8-tetrachlorodibenzodioxine multiple interactions ISO RGD:10533 6480464 Tetrachlorodibenzodioxin promotes the reaction [AHR protein binds to ERBB2 promoter] CTD PMID:19654925 2-acetamidofluorene increases expression EXP 6480464 2-Acetylaminofluorene results in increased expression of ERBB2 protein CTD PMID:11350689 2-deoxy-D-glucose multiple interactions ISO RGD:619563 6480464 [Deoxyglucose co-treated with Quercetin] results in increased ubiquitination of ERBB2 protein, Deoxyglucose inhibits the reaction [Quercetin promotes the reaction [ERBB2 protein binds to HSP90AA1 protein]] CTD PMID:18655187 2-hydroxypropanoic acid decreases expression ISO RGD:619563 6480464 Lactic Acid results in decreased expression of ERBB2 mRNA CTD PMID:30851411 3,3',5,5'-tetrabromobisphenol A increases expression EXP 6480464 tetrabromobisphenol A results in increased expression of ERBB2 mRNA CTD PMID:26353976 3,3'-diindolylmethane multiple interactions ISO RGD:619563 6480464 3 more ... CTD PMID:16580691 3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-heptadecafluoro-1-decanol decreases expression ISO RGD:619563 6480464 fluorotelomer alcohols results in decreased expression of ERBB2 mRNA CTD PMID:16393665 3,7-dihydropurine-6-thione decreases expression EXP 6480464 Mercaptopurine results in decreased expression of ERBB2 mRNA CTD PMID:23358152 3-isobutyl-1-methyl-7H-xanthine multiple interactions ISO RGD:619563 6480464 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ERBB2 mRNA CTD PMID:28628672 3-Nitrobenzanthrone decreases expression ISO RGD:619563 6480464 3-nitrobenzanthrone results in decreased expression of ERBB2 mRNA CTD PMID:34036453 3H-1,2-dithiole-3-thione increases expression EXP 6480464 1, 2-dithiol-3-thione results in increased expression of ERBB2 mRNA CTD PMID:19162173 4'-epidoxorubicin multiple interactions ISO RGD:619563 6480464 ERBB2 protein affects the susceptibility to [Epirubicin co-treated with CMF regimen], ERBB2 protein affects the susceptibility to [Fluorouracil co-treated with Epirubicin co-treated with Cyclophosphamide] CTD PMID:16446318 more ... 4-hydroxynon-2-enal decreases expression ISO RGD:619563 6480464 4-hydroxy-2-nonenal results in decreased expression of ERBB2 mRNA CTD PMID:12419474 4-nonylphenol decreases expression ISO RGD:619563 6480464 4-nonylphenol results in decreased expression of ERBB2 mRNA CTD PMID:16393665 5-fluorouracil multiple interactions ISO RGD:619563 6480464 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ERBB2 results in decreased susceptibility to Fluorouracil] more ... CTD PMID:15737843 more ... 5-fluorouracil affects expression ISO RGD:619563 6480464 Fluorouracil affects the expression of ERBB2 mRNA CTD PMID:15205334 5-fluorouracil decreases response to substance ISO RGD:619563 6480464 ERBB2 mRNA results in decreased susceptibility to Fluorouracil, ERBB2 results in decreased susceptibility to Fluorouracil CTD PMID:18337622 , PMID:21712253 6-propyl-2-thiouracil increases expression EXP 6480464 Propylthiouracil results in increased expression of ERBB2 mRNA CTD PMID:24780913 acetaldehyde affects expression ISO RGD:10533 6480464 Acetaldehyde affects the expression of ERBB2 mRNA CTD PMID:22634333 acetylsalicylic acid decreases expression ISO RGD:619563 6480464 Aspirin results in decreased expression of ERBB2 mRNA, Aspirin results in decreased expression of ERBB2 protein CTD PMID:19424877 acetylsalicylic acid increases expression ISO RGD:619563 6480464 Aspirin results in increased expression of ERBB2 mRNA CTD PMID:20457246 acrolein multiple interactions ISO RGD:619563 6480464 [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone] results in increased oxidation of ERBB2 mRNA, [Air Pollutants results in increased abundance of [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone]] which results in increased oxidation of ERBB2 mRNA CTD PMID:32699268 acrylamide decreases phosphorylation ISO RGD:619563 6480464 Acrylamide analog results in decreased phosphorylation of ERBB2 protein CTD PMID:10753475 acrylamide decreases expression EXP 6480464 Acrylamide results in decreased expression of ERBB2 mRNA CTD PMID:28959563 afimoxifene increases expression ISO RGD:10533 6480464 afimoxifene results in increased expression of ERBB2 mRNA CTD PMID:17640349 afimoxifene decreases expression ISO RGD:619563 6480464 afimoxifene results in decreased expression of ERBB2 mRNA CTD PMID:15072547 afimoxifene decreases response to substance ISO RGD:619563 6480464 ERBB2 results in decreased susceptibility to afimoxifene CTD PMID:21233418 afimoxifene multiple interactions ISO RGD:619563 6480464 afimoxifene inhibits the reaction [beta-hexachlorocyclohexane promotes the reaction [ERBB2 protein binds to ERBB3 protein]], afimoxifene inhibits the reaction [Estrogens results in decreased expression of ERBB2 mRNA] CTD PMID:12439862 , PMID:21233418 aflatoxin B1 increases expression EXP 6480464 Aflatoxin B1 results in increased expression of ERBB2 mRNA CTD PMID:33354967 aldehydo-D-glucose multiple interactions ISO RGD:619563 6480464 [Glucose deficiency co-treated with Quercetin] results in increased ubiquitination of ERBB2 protein, Glucose deficiency inhibits the reaction [Quercetin promotes the reaction [ERBB2 protein binds to HSP90AA1 protein]] CTD PMID:18655187 all-trans-retinoic acid decreases expression ISO RGD:619563 6480464 Tretinoin results in decreased expression of ERBB2 mRNA, Tretinoin results in decreased expression of ERBB2 protein CTD PMID:16752155 , PMID:21934132 all-trans-retinoic acid increases phosphorylation ISO RGD:10533 6480464 Tretinoin results in increased phosphorylation of ERBB2 protein CTD PMID:16357442 all-trans-retinoic acid multiple interactions ISO RGD:10533 6480464 HBEGF protein promotes the reaction [Tretinoin results in increased phosphorylation of ERBB2 protein] CTD PMID:16357442 alpha-pinene multiple interactions ISO RGD:619563 6480464 [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone] results in increased oxidation of ERBB2 mRNA, [Air Pollutants results in increased abundance of [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone]] which results in increased oxidation of ERBB2 mRNA CTD PMID:32699268 amiloride decreases phosphorylation ISO RGD:619563 6480464 Amiloride results in decreased phosphorylation of ERBB2 protein CTD PMID:16059913 ammonium chloride affects expression EXP 6480464 Ammonium Chloride affects the expression of ERBB2 mRNA CTD PMID:16483693 androgen antagonist multiple interactions EXP 6480464 [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of ERBB2 mRNA CTD PMID:25607892 anthra[1,9-cd]pyrazol-6(2H)-one multiple interactions ISO RGD:619563 6480464 pyrazolanthrone inhibits the reaction [ERBB2 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of CXCL8 mRNA]], pyrazolanthrone inhibits the reaction [ERBB2 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased secretion of CXCL8 protein]] CTD PMID:33396024 apigenin multiple interactions ISO RGD:619563 6480464 [Apigenin co-treated with Fluorouracil] results in decreased expression of ERBB2 protein CTD PMID:19885610 arsane multiple interactions ISO RGD:619563 6480464 [sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of ERBB2 mRNA more ... CTD PMID:32525701 , PMID:33396024 arsenic atom multiple interactions ISO RGD:619563 6480464 [sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of ERBB2 mRNA more ... CTD PMID:32525701 , PMID:33396024 arsenite(3-) multiple interactions ISO RGD:619563 6480464 [arsenite co-treated with tetrandrine] results in decreased expression of ERBB2 protein more ... CTD PMID:31646340 more ... arsenite(3-) decreases expression ISO RGD:619563 6480464 arsenite results in decreased expression of ERBB2 mRNA, arsenite results in decreased expression of ERBB2 protein CTD PMID:31646340 , PMID:31934280 arsenite(3-) affects response to substance ISO RGD:619563 6480464 ERBB2 affects the susceptibility to arsenite CTD PMID:31773452 benzo[a]pyrene multiple interactions ISO RGD:10533 6480464 Benzo(a)pyrene promotes the reaction [AHR protein binds to ERBB2 promoter] CTD PMID:19654925 benzo[a]pyrene affects methylation ISO RGD:619563 6480464 Benzo(a)pyrene affects the methylation of ERBB2 5' UTR CTD PMID:27901495 benzo[a]pyrene increases methylation ISO RGD:619563 6480464 Benzo(a)pyrene results in increased methylation of ERBB2 promoter CTD PMID:27901495 benzo[a]pyrene decreases expression ISO RGD:619563 6480464 Benzo(a)pyrene results in decreased expression of ERBB2 mRNA CTD PMID:16269432 more ... benzo[a]pyrene increases expression ISO RGD:619563 6480464 Benzo(a)pyrene results in increased expression of ERBB2 protein CTD PMID:32717239 Benzo[k]fluoranthene decreases expression ISO RGD:619563 6480464 benzo(k)fluoranthene results in decreased expression of ERBB2 mRNA CTD PMID:21635667 benzophenanthridine decreases expression ISO RGD:619563 6480464 Benzophenanthridines analog results in decreased expression of ERBB2 mRNA CTD PMID:23117580 berberine multiple interactions ISO RGD:619563 6480464 benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Berberine results in decreased expression of ERBB2 protein], Berberine results in decreased expression of and results in increased ubiquitination of ERBB2 protein CTD PMID:33325633 beta-hexachlorocyclohexane increases expression ISO RGD:10533 6480464 beta-hexachlorocyclohexane results in increased expression of ERBB2 mRNA CTD PMID:17640349 beta-hexachlorocyclohexane multiple interactions ISO RGD:619563 6480464 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [beta-hexachlorocyclohexane promotes the reaction [ERBB2 protein binds to ERBB3 protein]] more ... CTD PMID:12439862 beta-hexachlorocyclohexane increases activity ISO RGD:619563 6480464 beta-hexachlorocyclohexane results in increased activity of ERBB2 protein CTD PMID:11222871 , PMID:9443065 beta-hexachlorocyclohexane increases expression ISO RGD:619563 6480464 beta-hexachlorocyclohexane results in increased expression of ERBB2 protein CTD PMID:12948864 beta-naphthoflavone decreases expression ISO RGD:619563 6480464 beta-Naphthoflavone results in decreased expression of ERBB2 mRNA CTD PMID:32858204 bifenthrin affects binding ISO RGD:619563 6480464 bifenthrin binds to ERBB2 protein CTD PMID:32278787 bis(2-ethylhexyl) phthalate multiple interactions EXP 6480464 [Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of ERBB2 mRNA CTD PMID:25607892 bis(2-ethylhexyl) phthalate increases expression EXP 6480464 Diethylhexyl Phthalate results in increased expression of ERBB2 mRNA CTD PMID:29945229 bisdemethoxycurcumin increases response to substance ISO RGD:619563 6480464 ERBB2 protein results in increased susceptibility to bisdemethoxycurcumin CTD PMID:34291863 bisdemethoxycurcumin decreases expression ISO RGD:619563 6480464 bisdemethoxycurcumin results in decreased expression of ERBB2 protein CTD PMID:34291863 bisphenol A increases phosphorylation ISO RGD:10533 6480464 bisphenol A results in increased phosphorylation of ERBB2 protein CTD PMID:21988766 , PMID:32353937 bisphenol A increases expression ISO RGD:10533 6480464 bisphenol A results in increased expression of ERBB2 mRNA CTD PMID:32156529 , PMID:32353937 bisphenol A decreases expression EXP 6480464 bisphenol A results in decreased expression of ERBB2 mRNA CTD PMID:34947998 bisphenol A increases expression ISO RGD:619563 6480464 bisphenol A results in increased expression of ERBB2 mRNA CTD PMID:29275510 bisphenol A affects expression ISO RGD:619563 6480464 bisphenol A affects the expression of ERBB2 mRNA CTD PMID:30903817 bisphenol A affects expression EXP 6480464 bisphenol A affects the expression of ERBB2 mRNA CTD PMID:25181051 bisphenol A multiple interactions EXP 6480464 [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of ERBB2 mRNA CTD PMID:25607892 bisphenol A decreases expression ISO RGD:10533 6480464 bisphenol A results in decreased expression of ERBB2 mRNA CTD PMID:26063408 bisphenol F multiple interactions ISO RGD:619563 6480464 [bisphenol F co-treated with Fulvestrant] results in decreased methylation of ERBB2 gene, [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ERBB2 mRNA CTD PMID:28628672 , PMID:31601247 bortezomib multiple interactions ISO RGD:619563 6480464 Bortezomib promotes the reaction [lapatinib results in decreased phosphorylation of ERBB2 protein], lapatinib promotes the reaction [Bortezomib results in decreased phosphorylation of ERBB2 protein] CTD PMID:20701607 bortezomib decreases phosphorylation ISO RGD:619563 6480464 Bortezomib results in decreased phosphorylation of ERBB2 protein CTD PMID:20701607 bosutinib decreases phosphorylation EXP 6480464 bosutinib results in decreased phosphorylation of ERBB2 protein CTD PMID:18385429 butanal decreases expression ISO RGD:619563 6480464 butyraldehyde results in decreased expression of ERBB2 mRNA CTD PMID:26079696 Butylparaben multiple interactions EXP 6480464 [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of ERBB2 mRNA CTD PMID:25607892 cadmium atom multiple interactions ISO RGD:619563 6480464 Fulvestrant inhibits the reaction [Cadmium results in decreased expression of ERBB2 mRNA] CTD PMID:31646340 cadmium atom decreases expression ISO RGD:619563 6480464 Cadmium results in decreased expression of ERBB2 mRNA CTD PMID:31646340 caffeine affects phosphorylation ISO RGD:619563 6480464 Caffeine affects the phosphorylation of ERBB2 protein CTD PMID:35688186 canertinib multiple interactions ISO RGD:619563 6480464 Canertinib inhibits the reaction [EGF protein results in increased phosphorylation of ERBB2 protein] CTD PMID:18927496 cannabidiol multiple interactions ISO RGD:619563 6480464 [Oxygen co-treated with Ozone co-treated with Cannabidiol] results in decreased expression of ERBB2 mRNA more ... CTD PMID:32992648 cannabidiol decreases expression ISO RGD:619563 6480464 Cannabidiol results in decreased expression of ERBB2 mRNA CTD PMID:32992648 capsaicin decreases expression ISO RGD:619563 6480464 Capsaicin results in decreased expression of ERBB2 protein CTD PMID:19855437 capsaicin affects expression ISO RGD:619563 6480464 Capsaicin affects the expression of ERBB2 mRNA CTD PMID:19502594 captan decreases expression ISO RGD:10533 6480464 Captan results in decreased expression of ERBB2 mRNA CTD PMID:31558096 carbamazepine decreases expression ISO RGD:619563 6480464 Carbamazepine results in decreased expression of ERBB2 mRNA, Carbamazepine results in decreased expression of ERBB2 protein CTD PMID:16965676 , PMID:17147113 carbamazepine affects expression ISO RGD:10533 6480464 Carbamazepine affects the expression of ERBB2 mRNA CTD PMID:22634333 carbamazepine multiple interactions ISO RGD:619563 6480464 Carbamazepine results in increased degradation of and results in decreased expression of ERBB2 protein CTD PMID:17147113 carboplatin multiple interactions ISO RGD:619563 6480464 ERBB2 protein results in decreased susceptibility to [Cyclophosphamide co-treated with Thiotepa co-treated with Carboplatin] CTD PMID:16446318 CGP 52608 multiple interactions ISO RGD:619563 6480464 CGP 52608 promotes the reaction [RORA protein binds to ERBB2 gene] CTD PMID:28238834 chloroquine decreases expression ISO RGD:619563 6480464 Chloroquine results in decreased expression of ERBB2 protein CTD PMID:20332299 chloroquine multiple interactions ISO RGD:619563 6480464 Chloroquine inhibits the reaction [tephrosin results in increased degradation of ERBB2 protein] CTD PMID:20056314 chlorothalonil increases activity ISO RGD:619563 6480464 tetrachloroisophthalonitrile results in increased activity of ERBB2 protein CTD PMID:11222871 choline multiple interactions ISO RGD:10533 6480464 [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of ERBB2 mRNA CTD PMID:20938992 chromium(6+) affects expression ISO RGD:619563 6480464 chromium hexavalent ion affects the expression of ERBB2 mRNA CTD PMID:18053681 cisplatin multiple interactions ISO RGD:619563 6480464 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ERBB2 results in decreased susceptibility to Cisplatin] more ... CTD PMID:15737843 more ... cisplatin decreases expression ISO RGD:619563 6480464 Cisplatin results in decreased expression of ERBB2 mRNA CTD PMID:27392435 cisplatin affects response to substance ISO RGD:619563 6480464 ERBB2 protein affects the susceptibility to Cisplatin CTD PMID:10327070 cisplatin decreases response to substance ISO RGD:619563 6480464 ERBB2 mRNA results in decreased susceptibility to Cisplatin, ERBB2 results in decreased susceptibility to Cisplatin CTD PMID:18337622 , PMID:21712253 clozapine affects phosphorylation EXP 6480464 Clozapine affects the phosphorylation of ERBB2 protein CTD PMID:26961615 cobalt dichloride decreases expression ISO RGD:619563 6480464 cobaltous chloride results in decreased expression of ERBB2 mRNA CTD PMID:19376846 copper atom increases expression EXP 6480464 Copper deficiency results in increased expression of ERBB2 mRNA CTD PMID:26033743 copper(0) increases expression EXP 6480464 Copper deficiency results in increased expression of ERBB2 mRNA CTD PMID:26033743 copper(II) sulfate decreases expression ISO RGD:619563 6480464 Copper Sulfate results in decreased expression of ERBB2 mRNA CTD PMID:19549813 coumarin decreases phosphorylation ISO RGD:619563 6480464 coumarin results in decreased phosphorylation of ERBB2 protein CTD PMID:35688186 coumestrol multiple interactions ISO RGD:619563 6480464 [Coumestrol co-treated with resveratrol] results in decreased expression of ERBB2 mRNA CTD PMID:19167446 crocidolite asbestos decreases expression ISO RGD:619563 6480464 Asbestos, Crocidolite results in decreased expression of ERBB2 protein CTD PMID:15626777 Cruentaren A decreases expression ISO RGD:619563 6480464 cruentaren A results in decreased expression of ERBB2 protein CTD PMID:24450340 CU-O LINKAGE decreases expression ISO RGD:619563 6480464 cupric oxide results in decreased expression of ERBB2 mRNA CTD PMID:22077320 Cuprizon increases expression EXP 6480464 Cuprizone results in increased expression of ERBB2 mRNA CTD PMID:26577399 Cuprizon affects expression EXP 6480464 Cuprizone affects the expression of ERBB2 mRNA CTD PMID:27523638 curcumin multiple interactions ISO RGD:619563 6480464 [ERBB2 protein results in increased susceptibility to Curcumin analog] which results in decreased phosphorylation of AK1 protein more ... CTD PMID:17918158 , PMID:25866362 curcumin increases response to substance ISO RGD:619563 6480464 ERBB2 protein results in increased susceptibility to Curcumin, ERBB2 protein results in increased susceptibility to Curcumin analog CTD PMID:25866362 , PMID:34291863 curcumin increases degradation ISO RGD:619563 6480464 Curcumin analog results in increased degradation of ERBB2 protein CTD PMID:25866362 curcumin decreases expression ISO RGD:619563 6480464 Curcumin analog results in decreased expression of ERBB2 mRNA more ... CTD PMID:17041101 more ... cycloheximide multiple interactions ISO RGD:619563 6480464 [Cycloheximide co-treated with Estradiol] results in decreased expression of ERBB2 mRNA more ... CTD PMID:15072547 more ... cycloheximide increases degradation ISO RGD:619563 6480464 Cycloheximide results in increased degradation of ERBB2 protein CTD PMID:25866362 cycloheximide decreases expression ISO RGD:619563 6480464 Cycloheximide results in decreased expression of ERBB2 mRNA, Cycloheximide results in decreased expression of ERBB2 protein CTD PMID:15072547 more ... cyclophosphamide multiple interactions ISO RGD:619563 6480464 ERBB2 affects the susceptibility to [Doxorubicin co-treated with Cyclophosphamide co-treated with docetaxel] more ... CTD PMID:15834928 more ... cyclosporin A decreases expression ISO RGD:619563 6480464 Cyclosporine results in decreased expression of ERBB2 mRNA CTD PMID:20106945 more ... cyhalothrin affects binding ISO RGD:619563 6480464 cyhalothrin binds to ERBB2 protein CTD PMID:32278787 D-glucose multiple interactions ISO RGD:619563 6480464 [Glucose deficiency co-treated with Quercetin] results in increased ubiquitination of ERBB2 protein, Glucose deficiency inhibits the reaction [Quercetin promotes the reaction [ERBB2 protein binds to HSP90AA1 protein]] CTD PMID:18655187 DDE multiple interactions EXP 6480464 [Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of ERBB2 mRNA CTD PMID:25607892 DDT increases phosphorylation ISO RGD:619563 6480464 DDT results in increased phosphorylation of ERBB2 protein CTD PMID:9070211 delphinidin decreases phosphorylation ISO RGD:619563 6480464 delphinidin results in decreased phosphorylation of ERBB2 protein CTD PMID:18618485 demethoxycurcumin increases response to substance ISO RGD:619563 6480464 ERBB2 protein results in increased susceptibility to demethoxycurcumin CTD PMID:34291863 demethoxycurcumin multiple interactions ISO RGD:619563 6480464 benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [demethoxycurcumin results in increased degradation of ERBB2 protein], demethoxycurcumin results in decreased expression of and results in increased degradation of ERBB2 protein CTD PMID:34291863 dexamethasone multiple interactions ISO RGD:619563 6480464 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ERBB2 mRNA CTD PMID:28628672 dextran sulfate multiple interactions ISO RGD:10533 6480464 [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ERBB2 mRNA CTD PMID:29950665 dibenz[a,h]anthracene decreases expression ISO RGD:619563 6480464 1 more ... CTD PMID:16269432 dibutyl phthalate increases expression EXP 6480464 Dibutyl Phthalate results in increased expression of ERBB2 mRNA CTD PMID:17379624 dibutyl phthalate multiple interactions EXP 6480464 [Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of ERBB2 mRNA CTD PMID:25607892 dimethylarsinic acid multiple interactions EXP 6480464 Cacodylic Acid results in increased expression of and results in increased phosphorylation of ERBB2 protein CTD PMID:32890875 dioxygen multiple interactions ISO RGD:619563 6480464 [Oxygen co-treated with Ozone co-treated with Cannabidiol] results in decreased expression of ERBB2 mRNA more ... CTD PMID:32992648 dorsomorphin multiple interactions ISO RGD:619563 6480464 [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ERBB2 mRNA CTD PMID:27188386 doxorubicin multiple interactions ISO RGD:619563 6480464 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ERBB2 results in decreased susceptibility to Doxorubicin] more ... CTD PMID:15486187 more ... doxorubicin increases expression ISO RGD:619563 6480464 Doxorubicin results in increased expression of ERBB2 mRNA CTD PMID:29803840 doxorubicin increases expression EXP 6480464 Doxorubicin results in increased expression of ERBB2 protein CTD PMID:17308081 doxorubicin multiple interactions EXP 6480464 Doxorubicin promotes the reaction [HSP90AA1 protein binds to ERBB2 protein] more ... CTD PMID:17308081 , PMID:19801490 doxorubicin multiple interactions ISO RGD:10533 6480464 NRG1 protein affects the reaction [Doxorubicin affects the phosphorylation of ERBB2 protein] CTD PMID:15833803 doxorubicin decreases response to substance ISO RGD:619563 6480464 ERBB2 protein results in decreased susceptibility to Doxorubicin, ERBB2 results in decreased susceptibility to Doxorubicin CTD PMID:21712253 more ... doxorubicin affects response to substance ISO RGD:619563 6480464 ERBB2 protein affects the susceptibility to Doxorubicin CTD PMID:10327070 doxorubicin affects expression ISO RGD:619563 6480464 Doxorubicin affects the expression of ERBB2 mRNA CTD PMID:15205334 dutasteride increases expression ISO RGD:619563 6480464 Dutasteride results in increased expression of ERBB2 mRNA CTD PMID:17636412 elemental selenium increases expression ISO RGD:619563 6480464 Selenium results in increased expression of ERBB2 mRNA CTD PMID:19244175 elemental selenium multiple interactions ISO RGD:619563 6480464 [Selenium co-treated with Vitamin E] results in increased expression of ERBB2 mRNA CTD PMID:19244175 endosulfan decreases expression EXP 6480464 Endosulfan results in decreased expression of ERBB2 mRNA CTD PMID:29391264 endosulfan decreases expression ISO RGD:619563 6480464 Endosulfan results in decreased expression of ERBB2 mRNA CTD PMID:30090376 enzacamene multiple interactions EXP 6480464 [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of ERBB2 mRNA CTD PMID:25607892 epoxiconazole multiple interactions EXP 6480464 [Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of ERBB2 mRNA CTD PMID:25607892 ethanol increases expression ISO RGD:10533 6480464 Ethanol results in increased expression of ERBB2 mRNA CTD PMID:35149083 ethyl trans-caffeate affects expression ISO RGD:619563 6480464 ethyl caffeate affects the expression of ERBB2 protein CTD PMID:24892518 ethyl trans-caffeate multiple interactions ISO RGD:619563 6480464 ethyl caffeate affects the phosphorylation of and affects the activity of ERBB2 protein CTD PMID:24892518 etoposide multiple interactions ISO RGD:619563 6480464 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ERBB2 results in decreased susceptibility to Etoposide] more ... CTD PMID:21712253 , PMID:25866362 etoposide decreases expression ISO RGD:619563 6480464 Etoposide results in decreased expression of ERBB2 mRNA CTD PMID:15228094 etoposide decreases response to substance ISO RGD:619563 6480464 ERBB2 protein results in decreased susceptibility to Etoposide, ERBB2 results in decreased susceptibility to Etoposide CTD PMID:21712253 , PMID:25866362 etoposide affects response to substance ISO RGD:619563 6480464 ERBB2 protein affects the susceptibility to Etoposide CTD PMID:10327070 fipronil increases expression EXP 6480464 fipronil results in increased expression of ERBB2 mRNA CTD PMID:34044035 fisetin multiple interactions ISO RGD:619563 6480464 fisetin results in decreased phosphorylation of and results in increased degradation of ERBB2 protein CTD PMID:30431692 fludioxonil affects binding ISO RGD:619563 6480464 fludioxonil binds to ERBB2 protein CTD PMID:32278787 fluvalinate affects binding ISO RGD:619563 6480464 fluvalinate binds to ERBB2 protein CTD PMID:32278787 folic acid multiple interactions ISO RGD:10533 6480464 [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of ERBB2 mRNA CTD PMID:20938992 folpet decreases expression ISO RGD:10533 6480464 folpet results in decreased expression of ERBB2 mRNA CTD PMID:31558096 formaldehyde increases phosphorylation ISO RGD:619563 6480464 Formaldehyde results in increased phosphorylation of ERBB2 protein CTD PMID:36534342 fulvestrant increases expression ISO RGD:619563 6480464 Fulvestrant results in increased expression of ERBB2 mRNA CTD PMID:15072547 , PMID:31646340 fulvestrant multiple interactions ISO RGD:619563 6480464 [bisphenol F co-treated with Fulvestrant] results in decreased methylation of ERBB2 gene more ... CTD PMID:31601247 , PMID:31646340 fulvestrant affects response to substance ISO RGD:619563 6480464 ERBB2 affects the susceptibility to fulvestrant CTD PMID:24169358 furan increases expression EXP 6480464 furan results in increased expression of ERBB2 mRNA CTD PMID:27387713 gefitinib multiple interactions ISO RGD:619563 6480464 gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of and results in increased activity of ERBB2 protein], gefitinib results in decreased activity of [EGFR protein binds to ERBB2 protein] CTD PMID:17898861 gefitinib decreases phosphorylation ISO RGD:619563 6480464 gefitinib results in decreased phosphorylation of ERBB2 protein CTD PMID:16243822 geldanamycin multiple interactions ISO RGD:619563 6480464 [geldanamycin binds to HSP90B1 protein] inhibits the reaction [HSP90B1 protein binds to ERBB2 protein] more ... CTD PMID:18655187 , PMID:8617772 geldanamycin decreases expression ISO RGD:619563 6480464 geldanamycin results in decreased expression of ERBB2 protein CTD PMID:24450340 geldanamycin increases degradation ISO RGD:619563 6480464 geldanamycin results in increased degradation of ERBB2 protein CTD PMID:11071886 more ... genistein multiple interactions ISO RGD:619563 6480464 Genistein affects the reaction [[sodium arsenite results in increased abundance of Arsenic] which affects the phosphorylation of ERBB2 protein] more ... CTD PMID:33396024 gentamycin decreases expression EXP 6480464 Gentamicins results in decreased expression of ERBB2 mRNA CTD PMID:33387578 glucose multiple interactions ISO RGD:619563 6480464 [Glucose deficiency co-treated with Quercetin] results in increased ubiquitination of ERBB2 protein, Glucose deficiency inhibits the reaction [Quercetin promotes the reaction [ERBB2 protein binds to HSP90AA1 protein]] CTD PMID:18655187 haloperidol multiple interactions EXP 6480464 Haloperidol results in increased expression of and results in increased phosphorylation of ERBB2 protein CTD PMID:26961615 Heptachlor epoxide increases activity ISO RGD:619563 6480464 Heptachlor Epoxide results in increased activity of ERBB2 protein CTD PMID:11222871 hydrogen peroxide affects expression ISO RGD:619563 6480464 Hydrogen Peroxide affects the expression of ERBB2 mRNA CTD PMID:20044591 hydrogen peroxide decreases expression ISO RGD:619563 6480464 Hydrogen Peroxide results in decreased expression of ERBB2 mRNA CTD PMID:12419474 hydroquinone decreases expression ISO RGD:619563 6480464 hydroquinone results in decreased expression of ERBB2 mRNA CTD PMID:22245671 Indeno[1,2,3-cd]pyrene decreases expression ISO RGD:619563 6480464 indeno(1 more ... CTD PMID:21635667 indometacin multiple interactions ISO RGD:619563 6480464 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ERBB2 mRNA CTD PMID:28628672 irinotecan affects expression EXP 6480464 Irinotecan affects the expression of ERBB2 mRNA CTD PMID:20097248 iron(2+) sulfate (anhydrous) multiple interactions ISO RGD:619563 6480464 ferrous sulfate inhibits the reaction [Quercetin promotes the reaction [ERBB2 protein binds to HSP90AA1 protein]], ferrous sulfate inhibits the reaction [Quercetin results in decreased expression of and results in increased ubiquitination of ERBB2 protein] CTD PMID:18655187 kahweol multiple interactions ISO RGD:619563 6480464 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [kahweol results in decreased expression of ERBB2 mRNA] more ... CTD PMID:30205135 kahweol decreases expression ISO RGD:619563 6480464 kahweol results in decreased expression of ERBB2 mRNA, kahweol results in decreased expression of ERBB2 protein CTD PMID:30205135 L-methionine multiple interactions ISO RGD:10533 6480464 [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of ERBB2 mRNA CTD PMID:20938992 lactacystin multiple interactions ISO RGD:619563 6480464 lactacystin inhibits the reaction [Dronabinol results in decreased expression of ERBB2 protein] CTD PMID:30733293 lapatinib multiple interactions ISO RGD:619563 6480464 [Lapatinib results in decreased susceptibility to Lapatinib] which results in increased phosphorylation of ERBB2 protein more ... CTD PMID:20701607 more ... lapatinib decreases phosphorylation ISO RGD:10533 6480464 lapatinib results in decreased phosphorylation of ERBB2 protein CTD PMID:20197467 lapatinib decreases phosphorylation ISO RGD:619563 6480464 lapatinib results in decreased phosphorylation of ERBB2 protein CTD PMID:20701607 , PMID:26643609 lapatinib decreases expression ISO RGD:619563 6480464 lapatinib results in decreased expression of ERBB2 protein CTD PMID:16091755 lapatinib decreases activity ISO RGD:619563 6480464 lapatinib results in decreased activity of ERBB2 protein CTD PMID:15665275 more ... lead(0) decreases expression ISO RGD:619563 6480464 Lead results in decreased expression of ERBB2 mRNA CTD PMID:19921347 lead(2+) decreases expression ISO RGD:619563 6480464 Lead results in decreased expression of ERBB2 mRNA CTD PMID:19921347 lignan decreases expression ISO RGD:619563 6480464 Lignans results in decreased expression of ERBB2 protein CTD PMID:15897583 linuron multiple interactions EXP 6480464 [Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of ERBB2 mRNA CTD PMID:25607892 lithium chloride multiple interactions ISO RGD:619563 6480464 Lithium Chloride inhibits the reaction [ERBB2 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of CXCL8 mRNA]], Lithium Chloride inhibits the reaction [ERBB2 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased secretion of CXCL8 protein]] CTD PMID:33396024 LY294002 multiple interactions ISO RGD:619563 6480464 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ERBB2 results in decreased susceptibility to Cisplatin] more ... CTD PMID:12439862 more ... LY294002 decreases expression ISO RGD:619563 6480464 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased expression of ERBB2 mRNA CTD PMID:30205135 masoprocol multiple interactions ISO RGD:619563 6480464 Masoprocol inhibits the reaction [IGF1 protein results in increased phosphorylation of ERBB2 protein] CTD PMID:18645000 mechlorethamine decreases expression ISO RGD:619563 6480464 Mechlorethamine results in decreased expression of ERBB2 protein CTD PMID:17932452 mercaptopurine decreases expression EXP 6480464 Mercaptopurine results in decreased expression of ERBB2 mRNA CTD PMID:23358152 methotrexate affects response to substance ISO RGD:619563 6480464 ERBB2 protein affects the susceptibility to Methotrexate CTD PMID:10327070 methotrexate increases expression ISO RGD:619563 6480464 Methotrexate results in increased expression of ERBB2 mRNA CTD PMID:21678067 mitoxantrone multiple interactions ISO RGD:619563 6480464 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ERBB2 results in decreased susceptibility to Mitoxantrone] more ... CTD PMID:21712253 mitoxantrone decreases response to substance ISO RGD:619563 6480464 ERBB2 results in decreased susceptibility to Mitoxantrone CTD PMID:21712253 MK-2206 increases expression ISO RGD:619563 6480464 MK 2206 results in increased expression of ERBB2 protein CTD PMID:27897231 MK-2206 multiple interactions ISO RGD:619563 6480464 platycodin D inhibits the reaction [MK 2206 results in increased expression of ERBB2 protein] CTD PMID:27897231 N-acetylcysteamine multiple interactions ISO RGD:619563 6480464 2-acetamidoethanethiol analog results in decreased activity of and results in decreased phosphorylation of ERBB2 protein CTD PMID:20058253 N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal multiple interactions ISO RGD:619563 6480464 benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Berberine results in decreased expression of ERBB2 protein] more ... CTD PMID:18655187 more ... N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal decreases expression ISO RGD:619563 6480464 benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of ERBB2 mRNA, benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of ERBB2 protein CTD PMID:20332299 , PMID:31806706 N-ethyl-N-nitrosourea increases mutagenesis EXP 6480464 Ethylnitrosourea results in increased mutagenesis of ERBB2 gene CTD PMID:16651423 N-methyl-N'-nitro-N-nitrosoguanidine increases expression ISO RGD:619563 6480464 Methylnitronitrosoguanidine results in increased expression of ERBB2 mRNA CTD PMID:12634122 nitrogen mustard decreases expression ISO RGD:619563 6480464 Nitrogen Mustard Compounds results in decreased expression of ERBB2 mRNA CTD PMID:16417271 orlistat affects response to substance ISO RGD:619563 6480464 ERBB2 protein affects the susceptibility to orlistat CTD PMID:15870086 orlistat affects localization ISO RGD:619563 6480464 orlistat affects the localization of ERBB2 protein CTD PMID:15870086 orlistat decreases expression ISO RGD:619563 6480464 orlistat results in decreased expression of ERBB2 mRNA, orlistat results in decreased expression of ERBB2 protein CTD PMID:15870086 Oxyfluorfen affects binding ISO RGD:619563 6480464 oxyfluorofen binds to ERBB2 protein CTD PMID:32278787 ozone multiple interactions ISO RGD:619563 6480464 [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone] results in increased oxidation of ERBB2 mRNA more ... CTD PMID:32699268 , PMID:32992648 paclitaxel decreases response to substance ISO RGD:619563 6480464 ERBB2 protein results in decreased susceptibility to Paclitaxel, ERBB2 results in decreased susceptibility to Paclitaxel CTD PMID:21712253 , PMID:25866362 paclitaxel affects response to substance ISO RGD:619563 6480464 ERBB2 protein affects the susceptibility to Paclitaxel CTD PMID:10327070 paclitaxel multiple interactions ISO RGD:619563 6480464 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ERBB2 results in decreased susceptibility to Paclitaxel] more ... CTD PMID:16580691 more ... paracetamol decreases expression ISO RGD:619563 6480464 Acetaminophen results in decreased expression of ERBB2 mRNA CTD PMID:21420995 paracetamol increases expression EXP 6480464 Acetaminophen results in increased expression of ERBB2 mRNA CTD PMID:33387578 paracetamol multiple interactions EXP 6480464 [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of ERBB2 mRNA CTD PMID:25607892 paraquat multiple interactions ISO RGD:619563 6480464 NFE2L2 protein affects the reaction [ERBB2 protein results in decreased susceptibility to Paraquat] CTD PMID:25467193 paraquat decreases response to substance ISO RGD:619563 6480464 ERBB2 protein results in decreased susceptibility to Paraquat CTD PMID:25467193 perfluorooctane-1-sulfonic acid decreases expression EXP 6480464 perfluorooctane sulfonic acid results in decreased expression of ERBB2 mRNA CTD PMID:18692542 perfluorooctanoic acid decreases expression ISO RGD:619563 6480464 perfluorooctanoic acid results in decreased expression of ERBB2 protein CTD PMID:26879310 permethrin increases activity ISO RGD:619563 6480464 Permethrin results in increased activity of ERBB2 protein CTD PMID:11222871 phenylmercury acetate decreases expression ISO RGD:619563 6480464 Phenylmercuric Acetate results in decreased expression of ERBB2 mRNA CTD PMID:26272509 phenylmercury acetate multiple interactions ISO RGD:619563 6480464 [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ERBB2 mRNA CTD PMID:27188386 PhIP increases expression EXP 6480464 2-amino-1-methyl-6-phenylimidazo(4, 5-b)pyridine results in increased expression of ERBB2 mRNA CTD PMID:8603490 phorbol 13-acetate 12-myristate multiple interactions ISO RGD:619563 6480464 PIN1 protein promotes the reaction [Tetradecanoylphorbol Acetate results in increased expression of ERBB2 protein] CTD PMID:20479004 phorbol 13-acetate 12-myristate increases expression ISO RGD:619563 6480464 Tetradecanoylphorbol Acetate results in increased expression of ERBB2 protein CTD PMID:20479004 Pirarubicin multiple interactions ISO RGD:619563 6480464 ERBB2 protein affects the susceptibility to [Cyclophosphamide co-treated with pirarubicin co-treated with Fluorouracil] CTD PMID:15940066 platycodin D decreases expression ISO RGD:619563 6480464 platycodin D results in decreased expression of ERBB2 protein CTD PMID:27897231 platycodin D multiple interactions ISO RGD:619563 6480464 platycodin D inhibits the reaction [MK 2206 results in increased expression of ERBB2 protein] CTD PMID:27897231 prochloraz multiple interactions EXP 6480464 [Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of ERBB2 mRNA CTD PMID:25607892 procymidone multiple interactions EXP 6480464 [Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of ERBB2 mRNA CTD PMID:25607892 purine-6-thiol decreases expression EXP 6480464 Mercaptopurine results in decreased expression of ERBB2 mRNA CTD PMID:23358152 quercetin multiple interactions ISO RGD:619563 6480464 [Deoxyglucose co-treated with Quercetin] results in increased ubiquitination of ERBB2 protein more ... CTD PMID:12888923 , PMID:18655187 quercetin increases expression ISO RGD:619563 6480464 Quercetin results in increased expression of ERBB2 mRNA CTD PMID:14715546 quercetin decreases expression ISO RGD:619563 6480464 Quercetin results in decreased expression of ERBB2 protein CTD PMID:15741050 quercetin decreases phosphorylation ISO RGD:619563 6480464 Quercetin results in decreased phosphorylation of ERBB2 protein CTD PMID:18655187 quinazolines decreases phosphorylation ISO RGD:619563 6480464 Quinazolines analog results in decreased phosphorylation of ERBB2 protein CTD PMID:10753475 rac-lactic acid decreases expression ISO RGD:619563 6480464 Lactic Acid results in decreased expression of ERBB2 mRNA CTD PMID:30851411 raloxifene decreases response to substance ISO RGD:10533 6480464 ERBB2 protein results in decreased susceptibility to Raloxifene Hydrochloride CTD PMID:16609042 reparixin multiple interactions ISO RGD:619563 6480464 reparixin affects the reaction [[sodium arsenite results in increased abundance of Arsenic] which affects the phosphorylation of ERBB2 protein] CTD PMID:33396024 reserpine increases response to substance EXP 6480464 ERBB2 protein results in increased susceptibility to Reserpine CTD PMID:8093862 resveratrol multiple interactions ISO RGD:619563 6480464 [Coumestrol co-treated with resveratrol] results in decreased expression of ERBB2 mRNA more ... CTD PMID:16488535 more ... resveratrol decreases phosphorylation ISO RGD:619563 6480464 resveratrol results in decreased phosphorylation of ERBB2 protein CTD PMID:20729295 resveratrol decreases expression ISO RGD:10533 6480464 resveratrol results in decreased expression of ERBB2 CTD PMID:15688416 resveratrol increases expression ISO RGD:619563 6480464 resveratrol results in increased expression of ERBB2 mRNA, resveratrol results in increased expression of ERBB2 protein CTD PMID:16488535 resveratrol decreases expression ISO RGD:619563 6480464 resveratrol results in decreased expression of ERBB2 more ... CTD PMID:15688416 more ... Rhein decreases expression ISO RGD:619563 6480464 rhein results in decreased expression of ERBB2 protein CTD PMID:21457705 risperidone increases phosphorylation EXP 6480464 Risperidone results in increased phosphorylation of ERBB2 protein CTD PMID:26961615 romidepsin decreases expression ISO RGD:619563 6480464 romidepsin results in decreased expression of ERBB2 protein CTD PMID:15014036 SB 203580 multiple interactions ISO RGD:619563 6480464 SB 203580 inhibits the reaction [ERBB2 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of CXCL8 mRNA]], SB 203580 inhibits the reaction [ERBB2 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased secretion of CXCL8 protein]] CTD PMID:33396024 SB 431542 multiple interactions ISO RGD:619563 6480464 [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ERBB2 mRNA CTD PMID:27188386 selenium atom increases expression ISO RGD:619563 6480464 Selenium results in increased expression of ERBB2 mRNA CTD PMID:19244175 selenium atom multiple interactions ISO RGD:619563 6480464 [Selenium co-treated with Vitamin E] results in increased expression of ERBB2 mRNA CTD PMID:19244175 silicon dioxide decreases expression ISO RGD:619563 6480464 Silicon Dioxide analog results in decreased expression of ERBB2 mRNA CTD PMID:25895662 sodium arsenate multiple interactions ISO RGD:619563 6480464 [sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of ERBB2 mRNA CTD PMID:32525701 sodium arsenite increases expression ISO RGD:619563 6480464 sodium arsenite results in increased expression of ERBB2 mRNA CTD PMID:32599262 sodium arsenite increases expression EXP 6480464 sodium arsenite results in increased expression of ERBB2 mRNA CTD PMID:11241755 sodium arsenite increases phosphorylation ISO RGD:619563 6480464 sodium arsenite results in increased phosphorylation of ERBB2 protein CTD PMID:20043101 more ... sodium arsenite affects expression ISO RGD:619563 6480464 sodium arsenite affects the expression of ERBB2 protein CTD PMID:17384772 sodium arsenite multiple interactions ISO RGD:619563 6480464 [sodium arsenite results in increased abundance of Arsenic] which results in increased expression of and affects the phosphorylation of ERBB2 protein more ... CTD PMID:15734884 more ... SR 144528 multiple interactions ISO RGD:619563 6480464 SR 144528 inhibits the reaction [Dronabinol inhibits the reaction [ERBB2 protein binds to CNR2 protein]] more ... CTD PMID:30733293 sulindac sulfide multiple interactions ISO RGD:619563 6480464 benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [sulindac sulfide results in decreased expression of ERBB2 protein] CTD PMID:20332299 sulindac sulfide decreases expression ISO RGD:619563 6480464 sulindac sulfide results in decreased expression of ERBB2 protein CTD PMID:20332299 sulindac sulfone decreases expression ISO RGD:619563 6480464 sulindac sulfone results in decreased expression of ERBB2 protein CTD PMID:20332299 tamoxifen multiple interactions ISO RGD:619563 6480464 [ERBB2 protein results in increased activity of ESR1 protein] which results in decreased susceptibility to Tamoxifen, ERBB2 protein inhibits the reaction [PA2G4 protein results in increased susceptibility to Tamoxifen] CTD PMID:20179226 , PMID:20379846 tamoxifen decreases response to substance ISO RGD:619563 6480464 ERBB2 protein results in decreased susceptibility to Tamoxifen CTD PMID:15665275 more ... tamoxifen increases phosphorylation ISO RGD:619563 6480464 Tamoxifen results in increased phosphorylation of ERBB2 protein CTD PMID:17157789 tamoxifen increases phosphorylation ISO RGD:10533 6480464 Tamoxifen results in increased phosphorylation of ERBB2 protein CTD PMID:21138602 tamoxifen increases expression ISO RGD:10533 6480464 Tamoxifen results in increased expression of ERBB2 protein CTD PMID:21138602 tanespimycin multiple interactions ISO RGD:619563 6480464 tanespimycin results in increased degradation of and results in decreased expression of ERBB2 protein CTD PMID:16061882 tanespimycin decreases expression ISO RGD:619563 6480464 tanespimycin results in decreased expression of ERBB2 protein CTD PMID:24784839 , PMID:34291863 temozolomide increases expression ISO RGD:619563 6480464 Temozolomide results in increased expression of ERBB2 mRNA CTD PMID:31758290 tephrosin multiple interactions ISO RGD:619563 6480464 Chloroquine inhibits the reaction [tephrosin results in increased degradation of ERBB2 protein] more ... CTD PMID:20056314 tephrosin affects localization ISO RGD:619563 6480464 tephrosin affects the localization of ERBB2 protein CTD PMID:20056314 tert-butyl hydroperoxide decreases expression ISO RGD:619563 6480464 tert-Butylhydroperoxide results in decreased expression of ERBB2 mRNA CTD PMID:15336504 tetrachloromethane increases expression EXP 6480464 Carbon Tetrachloride results in increased expression of ERBB2 mRNA CTD PMID:33387578 tetraphene decreases expression ISO RGD:619563 6480464 benz(a)anthracene results in decreased expression of ERBB2 mRNA CTD PMID:21635667 thalidomide multiple interactions ISO RGD:619563 6480464 [ERBB2 protein co-treated with PIK3CA protein mutant form] results in increased susceptibility to Thalidomide metabolite CTD PMID:28745489 Thiotepa affects response to substance ISO RGD:619563 6480464 ERBB2 protein affects the susceptibility to Thiotepa CTD PMID:10327070 Thiotepa multiple interactions ISO RGD:619563 6480464 ERBB2 protein results in decreased susceptibility to [Cyclophosphamide co-treated with Thiotepa co-treated with Carboplatin] CTD PMID:16446318 titanium dioxide decreases expression ISO RGD:10533 6480464 titanium dioxide results in decreased expression of ERBB2 mRNA CTD PMID:23409001 titanium dioxide multiple interactions ISO RGD:10533 6480464 [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ERBB2 mRNA CTD PMID:29950665 tributylstannane increases expression ISO RGD:10533 6480464 tributyltin results in increased expression of ERBB2 mRNA CTD PMID:31939706 trichloroethene decreases expression ISO RGD:10533 6480464 Trichloroethylene results in decreased expression of ERBB2 mRNA CTD PMID:15363585 trichloroethene increases expression EXP 6480464 Trichloroethylene results in increased expression of ERBB2 mRNA CTD PMID:33387578 trimellitic anhydride decreases expression ISO RGD:10533 6480464 trimellitic anhydride results in decreased expression of ERBB2 mRNA CTD PMID:19042947 tyrphostin AG 1478 multiple interactions ISO RGD:619563 6480464 [RTKI cpd co-treated with AG-879] results in decreased phosphorylation of ERBB2 protein CTD PMID:18618485 undecane decreases expression EXP 6480464 undecane results in decreased expression of ERBB2 protein CTD PMID:17337753 urethane decreases expression ISO RGD:619563 6480464 Urethane results in decreased expression of ERBB2 mRNA CTD PMID:28818685 valproic acid decreases expression ISO RGD:619563 6480464 Valproic Acid results in decreased expression of ERBB2 mRNA CTD PMID:23179753 more ... valproic acid affects expression ISO RGD:619563 6480464 Valproic Acid affects the expression of ERBB2 mRNA CTD PMID:25979313 vincaleukoblastine affects response to substance ISO RGD:619563 6480464 ERBB2 protein affects the susceptibility to Vinblastine CTD PMID:10327070 vinclozolin multiple interactions EXP 6480464 [Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of ERBB2 mRNA CTD PMID:25607892 vitamin E multiple interactions ISO RGD:619563 6480464 [Selenium co-treated with Vitamin E] results in increased expression of ERBB2 mRNA CTD PMID:19244175 vorinostat decreases expression ISO RGD:619563 6480464 vorinostat results in decreased expression of ERBB2 mRNA, vorinostat results in decreased expression of ERBB2 protein CTD PMID:17218635 , PMID:27188386 vorinostat multiple interactions ISO RGD:619563 6480464 vorinostat results in increased ubiquitination of and results in increased degradation of and results in decreased expression of ERBB2 protein CTD PMID:16144943